Acquisition Alert Serimmune was acquired by Infinity Bio in June 2025, signaling a shift in strategic ownership and potential integration opportunities for diagnostic and therapeutic pipelines.

Immune Intelligence The company specializes in immune intelligence to decode human immune responses, offering a holistic platform that could complement diagnostics, vaccines, and therapeutics across infectious diseases and immune-related conditions.

LymeX Recognition As a Phase 1 LymeX Diagnostics Prize winner in 2022, Serimmune demonstrated credibility in Lyme disease diagnostics, presenting a potential avenue for partnerships or licensing in vector-borne disease testing.

Strategic Partners Backed by notable investors such as Illumina Ventures, LabCorp, and Merck, and with past collaborations (Twist Bioscience) and a leadership focus in business development, there are established channels and credibility to accelerate co-development deals.

Capable Scale With a lean team and a revenue range of zero to one million but a total funding of twenty-one million, there is likely appetite for collaboration on high-value programs that leverage their immune profiling capabilities to de-risk early-stage diagnostics and therapeutics.